The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Open accessThe DOI matches its Crossref record; 119 of the 140 references it cites were found in a registry or an index; 9 of the 77 sources its claims cite were checked for support.
Abstract
OBJECTIVE: The objective of the study was to develop clinical practice guidelines for the diagnosis of Cushing's syndrome. PARTICIPANTS: The Task Force included a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, five additional experts, a methodologist, and a medical writer. The Task Force received no corporate funding or remuneration. CONSENSUS PROCESS: Consensus was guided by systematic reviews of evidence and discussions. The guidelines were reviewed and approved sequentially by The Endocrine Society's CGS and Clinical Affairs Core Committee, members responding to a web posting, and The Endocrine Society Council. At each stage the Task Force incorporated needed changes in response to written comments. CONCLUSIONS: After excluding exogenous glucocorticoid use, we recommend testing for Cushing's syndrome in patients with multiple and progressive features compatible with the syndrome, particularly those with a high discriminatory value, and patients with adrenal incidentaloma. We recommend initial use of one test with high diagnostic accuracy (urine cortisol, late night salivary cortisol, 1 mg overnight or 2 mg 48-h dexamethasone suppression test). We recommend that patients with an abnormal result see an endocrinologist and undergo a second test, either one of the above or, in some cases, a serum midnight cortisol or dexamethasone-CRH test. Patients with concordant abnormal results should undergo testing for the cause of Cushing's syndrome. Patients with concordant normal results should not undergo further evaluation. We recommend additional testing in patients with discordant results, normal responses suspected of cyclic hypercortisolism, or initially normal responses who accumulate additional features over time.
Overview
CoChat Summary
TL;DR
This Endocrine Society guideline recommends case detection for Cushing's syndrome only in selected high-risk groups, initial testing with one of four high-accuracy tests, and confirmatory second testing before cause-directed evaluation. It emphasizes excluding exogenous glucocorticoids first and notes that most recommendations rest on very low- to low-quality evidence.
Key findings
- Exclude exogenous glucocorticoid exposure before biochemical testing (1QQQQ); test patients with multiple and progressive features, unusual features for age, children with decreasing height percentile and increasing weight, or adrenal incidentaloma compatible with adenoma, and recommend against widespread testing in other groups.
- Initial testing should use one of: urine free cortisol (at least two measurements), late-night salivary cortisol (two measurements), 1-mg overnight dexamethasone suppression test, or 48-h 2 mg/d dexamethasone suppression test; recommend against random serum cortisol/plasma ACTH, urinary 17-ketosteroids, insulin tolerance test, loperamide test, and cause-directed tests for initial diagnosis.
- Reported test performance includes late-night salivary cortisol sensitivity 92–100% and specificity 93–100%; pediatric UFC sensitivity about 89%; 1-mg DST at a 1.8 µg/dL cutoff sensitivity >95% with specificity 80%, rising to >95% specificity at a 5 µg/dL threshold; LDDST sensitivity 96% and specificity 70%; dexamethasone-CRH sensitivity 98% and specificity 60%.
- Special-population recommendations: use UFC and avoid dexamethasone testing in pregnancy; avoid dexamethasone testing with enzyme-inducing antiepileptics; suggest 1-mg overnight DST rather than UFC in severe renal failure; suggest UFC or midnight salivary cortisol rather than DSTs in suspected cyclic Cushing's; suggest 1-mg DST or late-night cortisol rather than UFC in adrenal incidentaloma.
Methods
- A six-member Task Force appointed by The Endocrine Society's Clinical Guidelines Subcommittee, including a chair, five additional experts, a methodologist, and a medical writer, received no corporate funding or remuneration; consensus was guided by systematic reviews and discussions and approved sequentially by Society bodies and members.
- Recommendations used the GRADE approach: strong recommendations phrased “we recommend” with number 1, weak recommendations “we suggest” with number 2; evidence quality ranged from QEEE (very low) to QQQQ (high), informed by best available research evidence and systematic reviews/meta-analyses of test accuracy.
- The guideline presents evidence, values, and remarks linked to each recommendation; technical remarks often reflect the panel's unsystematic observations applied to a typical patient.
Limitations
- Stated: the majority of recommendations are based on very low- to low-quality evidence, with limited data linking diagnostic strategies to patient-important outcomes and no higher-quality direct evidence available.
- Stated: published data often come from larger tertiary referral centers and may be biased toward more diagnostically challenging cases, higher pretest probability, and greater disease severity, potentially giving an overly sanguine view of test performance in unselected populations.
- Evident from the text: this is a consensus guideline rather than a primary study, and some technical recommendations rest on unsystematic panel observations; data on treating mild/subclinical Cushing's syndrome and adrenal incidentaloma are described as limited and conflicting.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 4 Not valid · 37 Not checked · 33 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Another study of 86 consecutive obese subjects referred to an endocrine clinic with diabetes mellitus, hypertension, and/or the polycystic ovary syndrome found a 5.8% incidence of Cushing's syndrome (35).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.3 Evidence
What the sources say
- Partly supportedcites [35] 35. Ness-Abramof R, Nabriski D, Apovian CM, Niven M, Weiss E, Shapiro MS, Shenkman L 2002 Overnight dexamethasone suppression test: a reliable screen for Cushing's syndrome in the obese. Obes Res 10:1217-1221 sourceExperimental — accuracy not yet measured
The Patients section describes 86 obese patients referred to an endocrine clinic, and the Results report five Cushing’s syndrome diagnoses—5/86, or approximately 5.8%, though the paper prints 5.7%. The copy does not say the patients were consecutive. It also reports that 51 had obesity alone, so diabetes, hypertension, and polycystic ovary disease do not describe the whole group. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The salivary glands express 11-hydroxysteroid dehydrogenase type 2 (11-HSD2), which converts the biologically active cortisol to inactive cortisone (75).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Remarks for late-night salivary cortisol
What the sources say
- Supportedcites [75] 75. Smith RE, Maguire JA, Stein-Oakley AN, Sasano H, Takahashi K, Fuku- shima K, Krozowski ZS 1996 Localization of 11-hydroxysteroid dehydro- genase type II in human epithelial tissues. J Clin Endocrinol Metab 81:3244 - 3248 source
The paper reports 11β-HSD2 in the ducts of human parotid and submandibular salivary glands (Abstract; Discussion, p. 3247). It describes the enzyme as inactivating glucocorticoids and discusses salivary cortisol-to-cortisone ratios (Introduction; Discussion, p. 3247), supporting the stated function. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Overall, the evidence in adults suggests that the accuracy of this test is similar to that of UFC (2).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Evidence for late-night salivary cortisol
What the sources say
- Supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 source
Table 3 (Conclusions; page unavailable) reports broadly similar pooled diagnostic likelihood ratios for midnight salivary cortisol and UFC. The Summary of findings notes that evidence for salivary cortisol is more limited, consistent with the citing sentence’s cautious wording. (LLM, conf=0.88)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“When the assay upper limit of normal is used as a criterion, the overall evidence supports the diagnostic accuracy of UFC in adults suspected of having Cushing's syndrome (2,51).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.1 Evidence for use of UFC
What the sources say
- Partly supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 sourceExperimental — accuracy not yet measured
The Summary of findings says UFC has substantial evidence supporting its use to detect Cushing’s syndrome, and the pooled results table reports diagnostic accuracy across 14 UFC studies. The Subgroup analyses section identifies an assay-upper-limit cutoff, but the reported UFC estimate is pooled across studies rather than shown specifically for that cutoff. The Conclusions also limit the apparent accuracy to referral practices enriched with patients with Cushing’s syndrome; performance in usual clinical practice remains unclear. Page numbers were not available in our copy. (LLM, conf=0.83)
- Supportedcites [51] 51. Pecori Giraldi F, Ambrogio AG, De Martin M, Fatti LM, Scacchi M, Cav- agnini F 2007 Specificity of first-line tests for the diagnosis of Cushing's syndrome: assessment in a large series. J Clin Endocrinol Metab 92:4123- 4129 source
The UFC results (p. 2) report 91.2% specificity in Cushing’s syndrome suspects when values above the assay’s reference range were considered abnormal. The Discussion (p. 5) identifies that threshold as the assay’s upper limit of normal and describes UFC as having superior diagnostic performance. The study assessed specificity, rather than diagnostic accuracy across all measures. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The four recommended tests have acceptable diagnostic accuracy when the suggested cutoff points are used (2,30).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4 Evidence
What the sources say
- Partly supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 sourceExperimental — accuracy not yet measured
The Conclusions state that commonly used tests appear highly accurate in referral practices with samples enriched for Cushing’s syndrome, but that their performance in usual clinical practice is unclear. The Data extraction section says the review used cutoffs chosen by the primary studies, selecting those with the best performance when several were available; it does not establish accuracy specifically at the suggested cutoff points. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [30] 30. Batista DL, Riar J, Keil M, Stratakis CA 2007 Diagnostic tests for children who are referred for the investigation of Cushing syndrome. Pediatrics 120: e575-e586 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
48 more claims · 3 with their cited sources checked
Create a free account to see all 82 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 12
- It may state two separate claims as one. 20
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early diagnosis of secondary hypertension and the institution of appropriate targeted treatment have the potential to cure hypertension in some patients or improve BP control/reduce the number of prescribed antihypertensive medications in others.”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [118]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, accurate serum cortisol measurement is essential for the correct diagnosis and management of adrenal pathologies.”
From Serum cortisol: an up-to-date assessment of routine assay performance (2016) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the reliability of almost all markers of HPA axis activity, particularly ACTH and 24-h urinary free cortisol (UFC), is low (3,14,23)”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, UFC should not be considered an adequate screening test for SH and should be used in combination with other tests or in specific populations (1,14).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“some authors have proposed higher (3 or 8 mg) dexamethasone doses (40,46,54,56), which however did not show a better performance (14,23,66).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measured
27 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“biochemical hypercortisolism is present in a large fraction (up to 10%).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“Libe et al. (32) reported 18%; Terzolo et al. (21) quoted 5-20%, depending on referral bias and diagnostic tests and criteria.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > Subsequent evaluation
“3.9.1 We suggest the additional use of the dexamethasone-CRH test or the midnight serum cortisol test in specific situations (Fig. 1, 1QEEE).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > METHOD OF DEVELOPMENT OF EVIDENCE-BASED RECOMMENDATIONS
“strong recommendations use the phrase "we recommend" and the number 1, and weak recommendations use the phrase "we suggest" and the number 2.”
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“with expertise in development and implementation of evidencebased guidelines (1).”
BackgroundCushing, H. (1964) · Journal of Neurosurgery · doi:10.3171/jns.1964.21.4.0318 · Cited by 851 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundThe Diagnosis and Differential Diagnosis of Cushing’s Syndrome and Pseudo-Cushing’s States
Newell-Price, J., Trainer, P., Besser, M., & Grossman, A. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0346 · Cited by 833
Self-citationGold, P. W., Loriaux, D. L., Roy, A., Kling, M. A., Calabrese, J. R., Kellner, C. H., Nieman, L. K., Post, R. M., Pickar, D., Gallucci, W., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198605223142101 · Cited by 766
Self-citationThe natural history of cushing's syndrome
Plotz, C. M., Knowlton, A. I., & Ragan, C. (1952) · The American Journal of Medicine · doi:10.1016/0002-9343(52)90027-2 · Cited by 763 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundTESTS OF PITUITARY-ADRENAL SUPPRESSIBILITY IN THE DIAGNOSIS OF CUSHING'S SYNDROME*
LIDDLE, G. W. (1960) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-20-12-1539 · Cited by 735
Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease
Wei, L., MacDonald, T. M., & Walker, B. R. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00007 · Cited by 730 · cited 1×
“These data are consistent with the increased cardiovascular mortality and morbidity reported in patients with iatrogenic Cushing’s syndrome secondary to the chronic use of synthetic corticosteroids (15).”
ResultMeasurements of Serum Free Cortisol in Critically Ill Patients
Hamrahian, A. H., Oseni, T. S., & Arafah, B. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa020266 · Cited by 726 · cited 1×
“are associated with decreased serum cortisol values (39, 46).”
BackgroundMorbidity and mortality in Cushing's disease: an epidemiological approach.
Etxabe, J., & Vazquez, J. A. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02486.x · Cited by 622 · cited 2×
“0-fold, compared with the general population (4, 5).”
BackgroundIncidence and Late Prognosis of Cushing’s Syndrome: A Population-Based Study1
Lindholm, J., Juul, S., Jørgensen, J. O. L., Astrup, J., Bjerre, P., Feldt-Rasmussen, U., Hagen, C., Jørgensen, J., Kosteljanetz, M., Kristensen, L. Ø., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7093 · Cited by 619 · cited 6×
“Because some patients with Cushing’s disease demonstrate suppressibility to dexamethasone, use of this diagnostic criterion J Clin Endocrinol Metab, May 2008, 93(5):1526–1540 jcem.”
BackgroundInfluential
Cited by
Items 401–500 of 2,716
Patel, V. N., Liu, C. J., Shiroishi, M. S., Hurth, K. M., Carmichael, J. D., Zada, G., & Toga, A. W. (2020) · Neuroradiology · doi:10.1007/s00234-020-02431-x · Cited by 50
Approach to the Patient with Primary Aldosteronism: Utility and Limitations of Adrenal Vein Sampling
Turcu, A. F., & Auchus, R. J. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa952 · Cited by 51
Diagnostic challenges in cyclic Cushing's syndrome: a systematic review
Nowak, E., Vogel, F., Albani, A., Braun, L., Rubinstein, G., Zopp, S., Ritzel, K., Beuschlein, F., Theodoropoulou, M., & Reincke, M. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00150-x · Cited by 54
Mel'nichenko, G. A., Dedov, I. I., Belaya, Z. E., Rozhinskaya, L. Y., Vagapova, G. R., Волкова, Н. И., Grigor’ev, A. Y., Grineva, E. N., Marova, E. I., Mkrtumayn, A. M., et al. (2015) · Problems of Endocrinology · doi:10.14341/probl201561255-77 · Cited by 62
Genetics of primary macronodular adrenal hyperplasia
Fragoso, M. C. B. V., Alencar, G. A., Lerario, A. M., Bourdeau, I., Almeida, M. Q., Mendonca, B. B., & Lacroix, A. (2015) · Journal of Endocrinology · doi:10.1530/joe-14-0568 · Cited by 46
Bansal, P., Lila, A., Goroshi, M., Jadhav, S., Lomte, N., Thakkar, K., Goel, A., Shah, A., Sankhe, S., Goel, N., et al. (2017) · Endocrine Connections · doi:10.1530/ec-17-0175 · Cited by 45
Zhou, J., Zhang, M., Bai, X., Cui, S., Pang, C., Lü, L., Pang, H., Guo, X., Wang, Y., & Xing, B. (2019) · International Journal of Endocrinology · doi:10.1155/2019/7159696 · Cited by 57
“In accordance with the 2008 Endocrine Society Clinical Practice Guidelines [19], all patients enrolled in our study were diagnosed with endogenous CS based on the presence of relevant clinical features combined with at least one altered biochemical test, including 24h urinary free cortisol (direct chemiluminescence im…”
MethodSteroid biomarkers in human adrenal disease
Rege, J., Turcu, A. F., Else, T., Auchus, R. J., & Rainey, W. E. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.01.018 · Cited by 52
“Alternatively, ACTH-dependent CS can result from Cushing disease, meaning an ACTH-secreting pituitary adenoma, from ectopic ACTH secretion, or rarely, from ectopic CRH production [132, 133].”
BackgroundMini-review of hair cortisol concentration for evaluation of Cushing syndrome
Hodes, A., Meyer, J., Lodish, M. B., Stratakis, C. A., & Zilbermint, M. (2018) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2018.1517043 · Cited by 46
Hypercortisolemia Recurrence in Cushing’s disease; a diagnostic challenge
Hinojosa-Amaya, J. M., Varlamov, E. V., McCartney, S., & Fleseriu, M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00740 · Cited by 45
Modern management of mild autonomous cortisol secretion
Delivanis, D. A., Athimulam, S., & Bancos, I. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1551 · Cited by 46
Park, J., De Luca, A., Dutton, H., Malcolm, J. C., & Doyle, M.-A. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00090 · Cited by 46
Arnaldi, G., Tirabassi, G., Papa, R., Furlani, G., Trementino, L., Cardinaletti, M., Faloia, E., & Boscaro, M. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0125 · Cited by 45
Hair cortisol in the evaluation of Cushing syndrome
Hodes, A., Lodish, M. B., Tirosh, A., Meyer, J., Belyavskaya, E., Lyssikatos, C., Rosenberg, K., Demidowich, A., Swan, J., Jonas, N., et al. (2017) · Endocrine · doi:10.1007/s12020-017-1231-7 · Cited by 44
“Practice Guideline for the diagnosis of this rare disease recommends the following initial tests for CS: 24 h urine free cortisol (UFC), 1-mg overnight or 2-mg 48 h dexamethasone suppression test, late night salivary cortisol, or combination of any of the above [1].”
InfluentialManagement of Endocrinopathies in Pregnancy: A Review of Current Evidence
Călina, D. C., Docea, A. O., Golokhvast, K. S., Sifakis, S., Tsatsakis, A. M., & Makrigiannakis, A. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16050781 · Cited by 54
“The recommended pharmacological agents are the steroidogenesis inhibitors metyrapone, ketoconazole, and mitotane [92,94].”
BackgroundCeccato, F., Antonelli, G., Frigo, A. C., Regazzo, D., Plebani, M., Boscaro, M., & Scaroni, C. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0644-8 · Cited by 44
“Patients with active malignancies or clear signs/symptoms of overt hypercortisolism (recent-onset easy bruising, facial plethora, proximal muscle weakness, or reddish purple striae >1 cm wide [1, 2]) were excluded.”
BackgroundMethodInfluentialShen, J., Sun, M., Zhou, B., & Yan, J. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0345 · Cited by 44
Goupil, R., Wolley, M. J., Ahmed, A. H., Gordon, R. D., & Stowasser, M. (2015) · Clinical Endocrinology · doi:10.1111/cen.12750 · Cited by 45
Hayes, L. D., Sculthorpe, N. F., Cunniffe, B., & Grace, F. (2016) · International Journal of Sports Medicine · doi:10.1055/s-0042-105649 · Cited by 55
An update on Cushing syndrome in pediatrics
Stratakis, C. A. (2018) · Annales d Endocrinologie · doi:10.1016/j.ando.2018.03.010 · Cited by 54
Tapia-Castillo, A., Baudrand, R., Vaidya, A., Campino, C., Allende, F. A., Valdivia, C. P., Vecchiola, A., Lagos, C. F., Fuentes, C., Solari, S., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01197 · Cited by 50
“25 and plasma renin activity (PRA) ,1 ng/mL*hr] or potential hypercortisolism [urinary free cortisol greater than reference interval for assay (16)] were also excluded for further analyses.”
MethodImpact of USP8 Gene Mutations on Protein Deregulation in Cushing Disease
Weigand, I., Knobloch, L., Flitsch, J., Saeger, W., Monoranu, C. M., Höfner, K., Herterich, S., Rotermund, R., Ronchi, C. L., Buchfelder, M., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02564 · Cited by 44
“126 Diagnosis of CD was performed according to established clinical, biochemical and 127 morphological criteria [31]; the same was true for other pituitary tumor entities.”
MethodCastro, M. A., Lázaro, C. R., Ramírez, P. A. P., Hernández, M. C., Núñez, M. A. S., & Marazuela, M. (2019) · Endocrine · doi:10.1007/s12020-019-02066-w · Cited by 51
Castro, M. A., Guevara, M. I., Gutiérrez, M. C., Ramírez, P. A. P., Gimeno, P. G., Hanzu, F. A., & Lamas, C. (2020) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2020.03.002 · Cited by 50
Belaya, Z. E., Rozhinskaya, L. Y., Mel'nichenko, G. A., Solodovnikov, A. G., Dragunova, N. V., Iljin, A. V., Dzeranova, L. K., & Dedov, I. I. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2268-y · Cited by 47
“The suppression of RANKL might be connected with one of the deleterious effects of GCs on the immune system of patients with endogenous CS in whom infection is a common complication and even cause of death [6, 44].”
BackgroundInfluentialAbnormal body composition in patients with adrenal adenomas
Delivanis, D. A., Hurtado Andrade, M. D., Cortes, T., Athimulam, S., Khanna, A., Atkinson, E., McKenzie, T., Takahashi, N., Moynagh, M. R., & Bancos, I. (2021) · European Journal of Endocrinology · doi:10.1530/eje-21-0458 · Cited by 43
Valizadeh, M., Ahmadi, A. R., Ebadinejad, A., Rahmani, F., & Abiri, B. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09723-y · Cited by 50
“At present, BIPSS is considered as the gold standard for CD diagnosis preoperatively [7].”
BackgroundAkehi, Y., Kawate, H., Murase, K., Nagaishi, R., Nomiyama, T., Nomura, M., Takayanagi, R., & Yanase, T. (2013) · Endocrine Journal · doi:10.1507/endocrj.ej12-0458 · Cited by 43
Clinicopathological correlates of adrenal Cushing's syndrome
Duan, K., Hernandez, K., & Mete, Ö. (2014) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2014-202612 · Cited by 48
Prete, A., Paragliola, R. M., Bottiglieri, F., Rota, C. A., Pontecorvi, A., Salvatori, R., & Corsello, S. M. (2016) · Endocrine · doi:10.1007/s12020-016-1007-5 · Cited by 44
Metabolomic Biomarkers in Urine of Cushing’s Syndrome Patients
Kotłowska, A., Puzyn, T., Sworczak, K., Stepnowski, P., & Szefer, P. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020294 · Cited by 43
“Biomarkers commonly assessed in clinical evaluation of Cushing’s syndrome are either salivary, urinary, or serum cortisol [26,27].”
BackgroundMiller, B. S., Turcu, A. F., Nanba, A. T., Hughes, D. T., Cohen, M. S., Gauger, P. G., & Auchus, R. J. (2017) · World Journal of Surgery · doi:10.1007/s00268-017-4311-1 · Cited by 47
“according to practice guidelines available at the time of diagnosis [26].”
MethodStewart, P. M., & Krone, N. P. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00015-8 · Cited by 61
Self-citationOßwald, A., Wang, R., Beuschlein, F., Hartmann, M. F., Wudy, S. A., Bidlingmaier, M., Zopp, S., Reincke, M., & Ritzel, K. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.04.004 · Cited by 43
Mizdrak, M., Kurir, T. T., & Božić, J. (2021) · Biomedicines · doi:10.3390/biomedicines9020174 · Cited by 56
“The diagnosis of hypercortisolism is usually established by a 1-mg dexamethasone suppression test (1-mg DST), midnight salivary cortisol, or elevated 24-h urine free cortisol [44].”
cAMP signaling in cortisol-producing adrenal adenoma
Calebiro, D., Di Dalmazi, G., Bathon, K., Ronchi, C. L., & Beuschlein, F. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0353 · Cited by 45
New developments in the medical treatment of Cushing's syndrome
van der Pas, R., de Herder, W. W., Hofland, L. J., & Feelders, R. A. (2012) · Endocrine-Related Cancer · doi:10.1530/erc-12-0191 · Cited by 42
“…phenotype with truncal and facial fat deposition, plethoric facial appearance, easy bruisability, and muscle and skin atrophy (Table 1), although the prevalence of these symptoms can be highly variable and in part related to the underlying cause of CS (Newell-Price et al. 2006, Nieman et al. 2008).”
BackgroundEffects of endogenous hypercortisolism on bone mRNA and microRNA expression in humans
Belaya, Z. E., Grebennikova, T. A., Mel'nichenko, G. A., Nikitin, A. G., Solodovnikov, A. G., Brovkina, O., Grigoriev, A. Y., Rozhinskaya, L. Y., & Dedov, I. I. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4241-7 · Cited by 43
“Excessive and continuous tissue exposure to endogenous GC results in a similar or an even more severe set of symptoms than is usually observed in patients subjected to chronic administration of supra-physiological doses of GC [3, 5].”
BackgroundOsteopathy in mild adrenal Cushing’s syndrome and Cushing disease
Frara, S., Allora, A., di Filippo, L., Formenti, A. M., Loli, P., Polizzi, E., Tradati, D., Ulivieri, F. M., & Giustina, A. (2021) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2021.101515 · Cited by 47
Tritos, N. A., & Biller, B. M. K. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-59602-4.00015-0 · Cited by 51
Self-citationThe degree of urinary hypercortisolism is not correlated with the severity of cushing’s syndrome
Guarnotta, V., Amato, M. C., Pivonello, R., Arnaldi, G., Ciresi, A., Trementino, L., Citarrella, R., Iacuaniello, D., Michetti, G., Simeoli, C., et al. (2016) · Endocrine · doi:10.1007/s12020-016-0914-9 · Cited by 45
Cardiovascular risk and mortality in patients with active and treated hypercortisolism
Li, D., El Kawkgi, O. M., Henriquez, A. F., & Bancos, I. (2020) · Gland Surgery · doi:10.21037/gs.2019.11.03 · Cited by 42
“Gland Surg 2020;9(1):43-58 | http://dx.”
BackgroundCarroll, T. B., Javorsky, B. R., & Findling, J. W. (2016) · Endocrine Practice · doi:10.4158/ep161380.or · Cited by 41
Self-citationGenere, N., Kaur, R. J., Athimulam, S., Thomas, M. A., Nippoldt, T. B., Norman, M. V., Singh, R. J., Grebe, S. K. G., & Bancos, I. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab724 · Cited by 43
Diagnostic workup of Cushing’s syndrome
Balomenaki, M., Margaritopoulos, D., Vassiliadi, D. A., & Tsagarakis, S. (2022) · Journal of Neuroendocrinology · doi:10.1111/jne.13111 · Cited by 46
Kuckuck, S., Lengton, R., Boon, M. R., Boersma, E. H., Penninx, B. W. J. H., Kavousi, M., & van Rossum, E. F. C. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13739 · Cited by 49
Primary aldosteronism associated with subclinical Cushing syndrome.
Fujimoto, K., Honjo, S., Tatsuoka, H., Hamamoto, Y., Kawasaki, Y., Matsuoka, A., Ikeda, H., Wada, Y., Sasano, H., & Koshiyama, H. (2013) · PubMed · doi:10.3275/8818 · Cited by 55
Rizzoni, D., Porteri, E., Ciuceis, C. D., Rodella, L. F., Paiardi, S., Rizzardi, N., Platto, C., Boari, G. E. M., Pilu, A., Tiberio, G. A. M., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1588 · Cited by 42
2 Diagnosis/differential diagnosis of Cushing's syndrome: a review of best practice
Newell-Price, J. D. C. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/s1521-690x(09)70003-x · Cited by 48
Self-citationDimopoulou, C., Ising, M., Pfister, H., Schopohl, J., Stalla, G. K., & Sievers, C. (2012) · Neuroendocrinology · doi:10.1159/000338408 · Cited by 41
Asuzu, D. T., Chatain, G. P., Hayes, C. P., Benzo, S., McGlotten, R., Keil, M. F., Beri, A., Sharma, S. T., Nieman, L. K., Lodish, M. B., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3908 · Cited by 42
Self-citationTumour lateralization in Cushing's disease by inferior petrosal sinus sampling with desmopressin
Feng, M., Liu, Z., Liu, X., Zhang, X., Bao, X., Yao, Y., Deng, K., Xing, B., Lian, W., Zhu, H., et al. (2017) · Clinical Endocrinology · doi:10.1111/cen.13505 · Cited by 40
CRH stimulation improves 18F-FDG-PET detection of pituitary adenomas in Cushing’s disease
Boyle, J. A., Patronas, N. J., Smirniotopoulos, J. G., Herscovitch, P., Dieckman, W., Millo, C., Maric, D., Chatain, G. P., Hayes, C. P., Benzo, S., et al. (2019) · Endocrine · doi:10.1007/s12020-019-01944-7 · Cited by 42
Self-citationRNA Sequencing and Somatic Mutation Status of Adrenocortical Tumors: Novel Pathogenetic Insights
Dalmazi, G. D., Altieri, B., Scholz, C. J., Sbiera, S., Luconi, M., Waldman, J., Kaštelan, D., Ceccato, F., Chiodini, I., Arnaldi, G., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa616 · Cited by 56
“” Both guidelines recommend the use of additional biochemical tests to confirm cortisol secretory autonomy and assess the degree of cortisol secretion, and MACS were defined in absence of clinical and catabolic signs of overt CS (13, 14).”
BackgroundMethodResultInfluentialRonchi, C. L., Sbiera, S., Leich, E., Tissier, F., Steinhauer, S., Deutschbein, T., Faßnacht, M., & Allolio, B. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2669 · Cited by 42
“Malignancy was defined according to recognized clinical, biochemical, and morphological criteria, whereas the biochemical diagnosis of cortisol hypersecretion was made according to established criteria (18).”
Savas, M., Wester, V. L., de Rijke, Y. B., Rubinstein, G., Zopp, S., Dorst, K., van den Berg, S. A. A., Beuschlein, F., Feelders, R. A., Reincke, M., et al. (2019) · Neuroendocrinology · doi:10.1159/000498886 · Cited by 41
Scalp hair cortisol for diagnosis of Cushing's syndrome
Wester, V. L., Reincke, M., Koper, J. W., van den Akker, E. L. T., Manenschijn, L., Berr, C. M., Fazel, J., de Rijke, Y. B., Feelders, R. A., & van Rossum, E. F. C. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0873 · Cited by 39
Diagnostic testing of autonomous cortisol secretion in adrenal incidentalomas
Ueland, G. Å., Grinde, T., Methlie, P., Kelp, O., Løvås, K., & Husebye, E. S. (2020) · Endocrine Connections · doi:10.1530/ec-20-0419 · Cited by 40
“8) Size of largest AI if bilateral, median mm (range) 28 (13-45) 33 (21-42)”
BackgroundRonchi, C. L., Leich, E., Sbiera, S., Weismann, D., Rosenwald, A., Allolio, B., & Fassnacht, M. (2012) · Neoplasia · doi:10.1593/neo.111758 · Cited by 40
“The biochemical diagnosis of cortisol hypersecretion was made according to established criteria [25].”
MethodBone turnover in patients with endogenous Cushing’s syndrome before and after successful treatment
Szappanos, Á., Tõke, J., Lippai, D., Patócs, A., Igaz, P., Szücs, N., Fütő, L., Gláz, E., Rácz, K., & Tóth, M. (2009) · Osteoporosis International · doi:10.1007/s00198-009-0978-y · Cited by 43
“The accuracy of OC expressed as AUC (0.9227) obtained by ROC analysis is only slightly lower than the accuracy of current diagnostic tests for the diagnosis of endogenous CS, such as urinary-free cortisol (0.9645), midnight serum cortisol (0.9730), overnight LDDST (0.9771), and 2-day 2-mg dexamethasone suppression tes…”
ResultInfluentialEvaluation of the DDAVP test in the diagnosis of Cushing's Disease
Rollin, G. A. F., Costenaro, F., Gerchman, F., Rodrigues, T. C., & Czepielewski, M. A. (2015) · Clinical Endocrinology · doi:10.1111/cen.12661 · Cited by 40
Update on subclinical Cushing's syndrome
Nieman, L. K. (2015) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000159 · Cited by 40
“Hence, many patients with ‘subclinical’ Cushing’s syndrome do have features of the syndrome, but lack those findings that are more often associated with severe hypercortisolism, such as wide purple striae, unusual infections, and proximal muscle weakness [3].”
BackgroundSelf-citationCushing’s syndrome: comparison between Cushing’s disease and adrenal Cushing’s
Hirsch, D., Shimon, I., Manisterski, Y., Aviran-Barak, N., Amitai, O., Nadler, V., Alboim, S., Kopel, V., & Tsvetov, G. (2018) · Endocrine · doi:10.1007/s12020-018-1709-y · Cited by 48
Evaluation of Plasma, Salivary, and Urinary Cortisol Levels for Diagnosis of Cushing’s Syndrome
SAKIHARA, S., KAGEYAMA, K., OKI, Y., DOI, M., IWASAKI, Y., TAKAYASU, S., MORIYAMA, T., TERUI, K., NIGAWARA, T., HIRATA, Y., et al. (2010) · Endocrine Journal · doi:10.1507/endocrj.k09e-340 · Cited by 40
Ortiz, D. I., Findling, J. W., Carroll, T. B., Javorsky, B. R., Carr, A. A., Evans, D. B., Yen, T. W., & Wang, T. S. (2016) · Surgery · doi:10.1016/j.surg.2015.05.034 · Cited by 39
Self-citationDanet‐Lamasou, M., Asselineau, J., Perez, P., Vivot, A., Nunes, M., Loiseau, H., San‐Galli, F., Cherifi‐Gatta, B., Corcuff, J., & Tabarin, A. (2015) · Clinical Endocrinology · doi:10.1111/cen.12534 · Cited by 39
Variability of late-night salivary cortisol in Cushing disease: a prospective study
Sandouk, Z., Johnston, P., Bunch, D., Wang, S., Bena, J., Hamrahian, A., & Kennedy, L. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02020 · Cited by 39
“The Endocrine Society guidelines suggest measurement of late-night salivary cortisol (LNSC) as the appropriate method of investigating for cyclical CS or variable hormonogenesis, as it is simple to perform repeatedly and, when samples are collected appropriately, accurate (7).”
MethodSurgical management of adrenocortical tumours
Miller, B. S., & Doherty, G. M. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.26 · Cited by 39
Adrenal Incidentalomas: Clinical Controversies and Modified Recommendations
Garrett, R. W., Nepute, J., Hayek, M. E., & Albert, S. G. (2016) · American Journal of Roentgenology · doi:10.2214/ajr.15.15475 · Cited by 42
“An overnight 1-mg dexamethasone suppression test for which the posttest serum cortisol level is abnormal (> 5 μg/dL) and the plasma level of adrenocorticotropic hormone suppressed is more sensitive than a 24-hour urinary free cortisol test but is less specific [37, 44].”
BackgroundCabergoline treatment for recurrent Cushing’s disease during pregnancy
Nakhleh, A., Saiegh, L., Reut, M., Sheikh‐Ahmad, M., Wirsansky, I., & Shechner, C. (2016) · HORMONES · doi:10.14310/horm.2002.1685 · Cited by 44
“Key words: Cabergoline, Cushing’s disease, Pregnancy HORMONES 2016, 15(3):453-458”
Albani, A., Theodoropoulou, M., & Reincke, M. (2017) · Clinical Endocrinology · doi:10.1111/cen.13457 · Cited by 41
Broersen, L. H. A., van Haalen, F. M., Biermasz, N. R., Lobatto, D. J., Verstegen, M. J. T., van Furth, W. R., Dekkers, O. M., & Pereira, A. M. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-019-1038-0 · Cited by 40
Zoli, M., Staartjes, V. E., Guaraldi, F., Friso, F., Rustici, A., Asioli, S., Sollini, G., Pasquini, E., Regli, L., Serra, C., et al. (2020) · Neurosurgical FOCUS · doi:10.3171/2020.3.focus2060 · Cited by 40
Ceccato, F., Marcelli, G., Martino, M., Concettoni, C., Brugia, M., Trementino, L., Michetti, G., & Arnaldi, G. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0921-1 · Cited by 38
Daily salivary cortisol and cortisone rhythm in patients with adrenal incidentaloma
Ceccato, F., Barbot, M., Albiger, N., Antonelli, G., Zilio, M., Todeschini, M., Regazzo, D., Plebani, M., Lacognata, C., Iacobone, M., et al. (2018) · Endocrine · doi:10.1007/s12020-017-1421-3 · Cited by 38
Vogg, N., Kurlbaum, M., Deutschbein, T., Gräsl, B., Fassnacht, M., & Kroiss, M. (2021) · Clinical Chemistry · doi:10.1093/clinchem/hvab056 · Cited by 38
“8 mg/dL post Dex underwent further workup according to current guidelines (5, 11).”
MethodMinnetti, M., Hasenmajer, V., Sbardella, E., Angelini, F., Simeoli, C., Di Paola, N., Cozzolino, A., Pivonello, C., De Alcubierre, D., Chiloiro, S., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0454 · Cited by 39
Diagnostic value of salivary cortisol in Cushing's syndrome (CS)
Cardoso, E. M. L., Arregger, A. L., Tumilasci, O. R., & Contreras, L. N. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03381.x · Cited by 38
Screening for Cushing’s syndrome: Is it worthwhile?
Shimon, I. (2015) · Pituitary · doi:10.1007/s11102-015-0634-9 · Cited by 44
“The tests employed have different sensitivities and specificities for the detection of hypercortisolism [2].”
Hempen, C., Elfering, S., Mulder, A. H. L., van den Bergh, F. A. J. T. M., & Maatman, R. G. H. J. (2012) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1258/acb.2011.011004 · Cited by 38
Wester, V. L., Noppe, G., Savas, M., van den Akker, E. L. T., de Rijke, Y. B., & van Rossum, E. F. C. (2017) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2017.02.024 · Cited by 44
“Cortisol levels are usually measured in blood, saliva and urine (Nieman et al., 2008), but are highly variable due to the diurnal rhythm and the influence of acute stress (Tsigos and Chrousos, 2002).”
BackgroundGagnon, N., Fréchette, I., Mallet, P., Dubé, J., Houde, G., & Fink, G. D. (2018) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2018.02.012 · Cited by 39
Abujaber, F., Ricardo, A. I. C., Ríos, Á., Bernardo, F. J. G., & Martín-Doimeadios, R. C. R. (2018) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2018.12.001 · Cited by 42
Paraneoplastic syndromes in lung cancer and their management
Anwar, A., Jafri, F. M., Ashraf, S., Jafri, M. A. S., & Fanucchi, M. P. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.04.86 · Cited by 42
Sesta, A., Cassarino, M. F., Terreni, M., Ambrogio, A. G., Libera, L., Bardelli, D., Lasio, G. B., Losa, M., & Giraldi, F. P. (2019) · Neuroendocrinology · doi:10.1159/000500688 · Cited by 38
Endocrine Causes of Hypertension
de Silva, T., Cosentino, G., Ganji, S. S., Riera-Gonzalez, A., & Hsia, D. S. (2020) · Current Hypertension Reports · doi:10.1007/s11906-020-01108-3 · Cited by 44
The Mechanisms Underlying Autonomous Adrenocorticotropic Hormone Secretion in Cushing’s Disease
Fukuoka, H., Shichi, H., Yamamoto, M., & Takahashi, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239132 · Cited by 44
“These provocative and inhibitory tests are used to screen the patients for Cushing’s syndrome and act as a diagnostic tool to differentiate it from ectopic ACTH syndrome (EAS) or non-neoplastic hypercortisolemia (NNH, also known as pseudo-Cushing’s syndrome) [2,3].”
MethodManagement and Medical Therapy of Mild Hypercortisolism
Favero, V., Cremaschi, A., Falchetti, A., Gaudio, A., Gennari, L., Scillitani, A., Vescini, F., Morelli, V., Aresta, C., & Chiodini, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111521 · Cited by 43
“As adrenal incidentalomas are thought to be present in up to 7% of individuals above 60 years of age, a condition of HidHyCo is estimated to be present in 0.8–2% of the elderly population, a prevalence, thus, definitely higher than that reported in for CS [18,19].”
BackgroundMethodInfluentialEndocrine abnormality in paraneoplastic syndrome
Onyema, M. C., Drakou, E. E., & Dimitriadis, G. K. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101621 · Cited by 46
The morning and late‐night salivary cortisol ranges for healthy women may be used in pregnancy
Ambroziak, U., Kondracka, A., Bartoszewicz, Z., Krasnodębska‐Kiljańska, M., & Bednarczuk, T. (2015) · Clinical Endocrinology · doi:10.1111/cen.12853 · Cited by 38
Fustinoni, S., Polledri, E., & Mercadante, R. (2013) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.6601 · Cited by 41
Dogra, P., Šambula, L., Saini, J., Thangamuthu, K., Athimulam, S., Delivanis, D. A., Baikousi, D. A., Nathani, R., Zhang, C. D., Genere, N., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad113 · Cited by 38
Detomas, M., Altieri, B., Deutschbein, T., Faßnacht, M., & Dischinger, U. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.903545 · Cited by 43
Cardiovascular risk and white matter lesions after endocrine control of Cushing's syndrome
Santos, A., Resmini, E., Gómez-Ansón, B., Crespo, I., Granell, E., Valassi, E., Pires, P., Vives-Gilabert, Y., Martínez-Momblán, M. A., de Juan, M., et al. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0600 · Cited by 37
Valassi, E., Crespo, I., Keevil, B. G., Aulinas, A., Urgell, E., Vives, A. S., Trainer, P. J., & Webb, S. M. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0779 · Cited by 46
Law, M., Wang, R., Liu, C. J., Shiroishi, M. S., Carmichael, J. D., Mack, W. J., Weiss, M. H., Wang, D. J. J., Toga, A. W., & Zada, G. (2018) · Journal of neurosurgery · doi:10.3171/2017.9.jns171969 · Cited by 42
Moreira, A. C., Antonini, S. R. R., & de Castro, M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0102 · Cited by 41
Clinical Characteristics and Follow-Up Results of Adrenal Incidentaloma
Yılmaz, N., Avşar, E., Tazegül, G., Sarı, R., Altunbaş, H., & Balcı, M. K. (2020) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1079-4915 · Cited by 43
Fan, Y., Li, Y., Bao, X., Zhu, H., Lü, L., Yao, Y., Li, Y., Su, M., Feng, F., Feng, S., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa698 · Cited by 45
Castro, M. A., Mariño‐Sánchez, F., Cancela, A. A., Fernández, A. G., Duque, S. G., & Berrocal, V. R. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01448-6 · Cited by 38
Metadata
- Authors
- Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M.
- Affiliations
- National Institutes of Health (US)
- Massachusetts General Hospital (US)
- Medical College of Wisconsin (US)
- University of Sheffield (GB)
- Queen Mary University of London (GB)
- University of Birmingham (GB)
- Mayo Clinic (V.M.M.), Rochester, Minnesota 55905
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2008-05-01
- Volume
- 93
- Issue
- 5
- Pages
- 1526-1540
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC2386281
- OpenAlex
- W1990995386
- Cited by
- 2,718
- References
- 140
- Citations by year
- 2026: 159 · 2025: 173 · 2024: 173 · 2023: 148 · 2022: 212 · 2021: 199 · 2020: 195 · 2019: 165 · 2018: 150 · 2017: 148 · 2016: 158 · 2015: 156 · 2014: 134 · 2013: 139 · 2012: 114
- FWCI
- 70.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- European Society of Endocrinology
- National Institutes of Health
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (Z01HD008833)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- Cushing's syndrome, diagnosis, hypercortisolism, adrenal incidentaloma, dexamethasone suppression test, late-night salivary cortisol, urine cortisol
- MeSH terms
- Cushing Syndrome, Dexamethasone, Humans, Hydrocortisone, Saliva, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.